JP2012514601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514601A5 JP2012514601A5 JP2011544638A JP2011544638A JP2012514601A5 JP 2012514601 A5 JP2012514601 A5 JP 2012514601A5 JP 2011544638 A JP2011544638 A JP 2011544638A JP 2011544638 A JP2011544638 A JP 2011544638A JP 2012514601 A5 JP2012514601 A5 JP 2012514601A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimido
- diazepine
- methyl
- methoxy
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carbocycle Chemical group 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 125000003118 aryl group Chemical group 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 150000002148 esters Chemical class 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- PKVNVXXWANAAFP-UHFFFAOYSA-N 1,7-dihydro-1,4-diazepin-6-one Chemical compound O=C1CNC=CN=C1 PKVNVXXWANAAFP-UHFFFAOYSA-N 0.000 claims 3
- AZQDLBJZOAHSAZ-UHFFFAOYSA-N 1,7-dihydrodiazepin-6-one Chemical compound O=C1CNN=CC=C1 AZQDLBJZOAHSAZ-UHFFFAOYSA-N 0.000 claims 3
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 claims 3
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- BUBBBFSEOYHUQA-UHFFFAOYSA-N 2,5-dihydrooxazepin-6-one Chemical compound O1NC=CCC(C1)=O BUBBBFSEOYHUQA-UHFFFAOYSA-N 0.000 claims 2
- VVPYTOVXFOGRIN-UHFFFAOYSA-N 2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N(CC1)CCC1N1CCN(C)CC1 VVPYTOVXFOGRIN-UHFFFAOYSA-N 0.000 claims 2
- LZNDHLKMOBVBFV-UHFFFAOYSA-N 4-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 LZNDHLKMOBVBFV-UHFFFAOYSA-N 0.000 claims 2
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 claims 2
- QAPAJIZPZGWAND-UHFFFAOYSA-N XMD8-92 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 QAPAJIZPZGWAND-UHFFFAOYSA-N 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- NFNBVXVXMQZSGB-UHFFFAOYSA-N 11-cyclopentyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1=CC=CC=C1N2C1CCCC1 NFNBVXVXMQZSGB-UHFFFAOYSA-N 0.000 claims 1
- JGVXSQJYBQAPAE-UHFFFAOYSA-N 11-ethyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(CC)C3=CC=CC=C3C(=O)N(C)C2=CN=C1NC(C(=C1)OC)=CC=C1N1CCN(C)CC1 JGVXSQJYBQAPAE-UHFFFAOYSA-N 0.000 claims 1
- ASAFHHFHFUCJHM-UHFFFAOYSA-N 11-methyl-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)NC3=CN=2)C(OC(C)C)=CC=1N1CCN(C)CC1 ASAFHHFHFUCJHM-UHFFFAOYSA-N 0.000 claims 1
- LHBAORXBTTWPDF-UHFFFAOYSA-N 2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5-methyl-9-phenyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CCOC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1=CC=CC=C1 LHBAORXBTTWPDF-UHFFFAOYSA-N 0.000 claims 1
- DDTPGANIPBKTNU-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methyl-1-piperazinyl)anilino]-5,11-dimethyl-6-pyrimido[4,5-b][1,4]benzodiazepinone Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 DDTPGANIPBKTNU-UHFFFAOYSA-N 0.000 claims 1
- KXCGZEPWZFXPSC-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-4,11-dimethyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)NC3=C(C)N=2)C(OC)=CC=1N1CCN(C)CC1 KXCGZEPWZFXPSC-UHFFFAOYSA-N 0.000 claims 1
- OXTSNXXVWGKOMB-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-4,5,11-trimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=C(C)N=2)C(OC)=CC=1N1CCN(C)CC1 OXTSNXXVWGKOMB-UHFFFAOYSA-N 0.000 claims 1
- WBPCKVJWZORAAO-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dihydropyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3NC4=CC=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 WBPCKVJWZORAAO-UHFFFAOYSA-N 0.000 claims 1
- NYHLZQOMTUZDHV-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,8,11-trimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(C)C=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 NYHLZQOMTUZDHV-UHFFFAOYSA-N 0.000 claims 1
- YYTFTZONXCQXLW-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methyl-11-propan-2-ylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C(C)C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 YYTFTZONXCQXLW-UHFFFAOYSA-N 0.000 claims 1
- GTCWEOILNAZCDT-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methyl-11h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3NC4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 GTCWEOILNAZCDT-UHFFFAOYSA-N 0.000 claims 1
- NTRCYAXJQIZACU-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrimido[4,5-b][1,4]benzothiazepin-6-one Chemical compound C=1C=C(NC=2N=C3SC4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 NTRCYAXJQIZACU-UHFFFAOYSA-N 0.000 claims 1
- OGHDOVJGVKNHRQ-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5h-pyrimido[4,5-b][1,4]benzothiazepin-6-one Chemical compound C=1C=C(NC=2N=C3SC4=CC=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 OGHDOVJGVKNHRQ-UHFFFAOYSA-N 0.000 claims 1
- KBULREVCYROFNX-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8,11-dimethyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(C)C=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 KBULREVCYROFNX-UHFFFAOYSA-N 0.000 claims 1
- HQHQZEUABJAAMZ-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-9-phenyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CCN2C1=CC=CC=C1 HQHQZEUABJAAMZ-UHFFFAOYSA-N 0.000 claims 1
- UDMGPKXTQNCFIO-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazine-1-carbonyl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N1CCN(C)CC1 UDMGPKXTQNCFIO-UHFFFAOYSA-N 0.000 claims 1
- XYKSVLLNDQRZDK-UHFFFAOYSA-N 2-[2-methoxy-5-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C1=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=C1C(=O)N(CC1)CCC1N1CCN(C)CC1 XYKSVLLNDQRZDK-UHFFFAOYSA-N 0.000 claims 1
- YSFFGUHMDPYPAW-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCC(O)CC1 YSFFGUHMDPYPAW-UHFFFAOYSA-N 0.000 claims 1
- NPRYKZQCTXZUKH-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC(C)C)=CC=1N1CCC(O)CC1 NPRYKZQCTXZUKH-UHFFFAOYSA-N 0.000 claims 1
- NGXGUOYOCNOKJO-UHFFFAOYSA-N 2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-5-methyl-9-phenyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CC(C)OC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1=CC=CC=C1 NGXGUOYOCNOKJO-UHFFFAOYSA-N 0.000 claims 1
- RUSIEYRQPZZDCO-UHFFFAOYSA-N 2-[4-[4-(2-hydroxyethyl)piperazine-1-carbonyl]-2-methoxyanilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N1CCN(CCO)CC1 RUSIEYRQPZZDCO-UHFFFAOYSA-N 0.000 claims 1
- YMOOMBLIPWGVAG-UHFFFAOYSA-N 2-[[5-(4-hydroxypiperidin-1-yl)pyridin-2-yl]amino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 YMOOMBLIPWGVAG-UHFFFAOYSA-N 0.000 claims 1
- FMJVGPKPZYQCHQ-UHFFFAOYSA-N 2-cyclopentyl-13-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-9-methyl-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-8-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 FMJVGPKPZYQCHQ-UHFFFAOYSA-N 0.000 claims 1
- FWCFYOYWYWAYRZ-UHFFFAOYSA-N 2-cyclopentyl-13-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-9-methyl-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-8-one Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 FWCFYOYWYWAYRZ-UHFFFAOYSA-N 0.000 claims 1
- YXQSBQOOYOWCJL-UHFFFAOYSA-N 3-[(5,11-dimethyl-6-oxopyrimido[4,5-b][1,4]benzodiazepin-2-yl)amino]-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1NC1=NC=C(N(C)C(=O)C=2C(=CC=CC=2)N2C)C2=N1 YXQSBQOOYOWCJL-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- XBWVKVCSCJYKTP-UHFFFAOYSA-N 4-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-3-methoxy-N-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 XBWVKVCSCJYKTP-UHFFFAOYSA-N 0.000 claims 1
- REFAILJSNNDVNL-UHFFFAOYSA-N 4-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 REFAILJSNNDVNL-UHFFFAOYSA-N 0.000 claims 1
- WSLOEKAMNQLCHA-UHFFFAOYSA-N 4-[(5,11-dimethyl-6-oxopyrimido[4,5-b][1,4]benzodiazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C=2C(=CC=CC=2)N2C)C2=N1 WSLOEKAMNQLCHA-UHFFFAOYSA-N 0.000 claims 1
- JFRNFMQDZRWAQB-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 JFRNFMQDZRWAQB-UHFFFAOYSA-N 0.000 claims 1
- YPTCBEGMGVTHLV-UHFFFAOYSA-N 4-[(9-cyclopentyl-6-oxo-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CCN2C1CCCC1 YPTCBEGMGVTHLV-UHFFFAOYSA-N 0.000 claims 1
- 102100022681 40S ribosomal protein S27 Human genes 0.000 claims 1
- HGOKWKGWPGOSCA-UHFFFAOYSA-N 5-ethyl-2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]-11-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(CC)C2=CN=C1NC(C(=C1)OC)=CC=C1N1CCC(O)CC1 HGOKWKGWPGOSCA-UHFFFAOYSA-N 0.000 claims 1
- UJDYKWMGSWQRHC-UHFFFAOYSA-N 5-ethyl-2-[[5-(4-hydroxypiperidin-1-yl)pyridin-2-yl]amino]-11-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(CC)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 UJDYKWMGSWQRHC-UHFFFAOYSA-N 0.000 claims 1
- NGLWEPBNFIVDCQ-UHFFFAOYSA-N 6-[(2-cyclopentyl-9-methyl-8-oxo-2,9,12,14-tetrazatricyclo[8.4.0.03,7]tetradeca-1(14),10,12-trien-13-yl)amino]-N-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 NGLWEPBNFIVDCQ-UHFFFAOYSA-N 0.000 claims 1
- MUKRTRBUCKPVNQ-UHFFFAOYSA-N 8-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-11-methyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(Cl)C=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 MUKRTRBUCKPVNQ-UHFFFAOYSA-N 0.000 claims 1
- VHGSQSKYNALGRI-UHFFFAOYSA-N 8-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=C(Cl)C=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 VHGSQSKYNALGRI-UHFFFAOYSA-N 0.000 claims 1
- RHSOYHKODVPGTH-UHFFFAOYSA-N 9-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC(Cl)=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 RHSOYHKODVPGTH-UHFFFAOYSA-N 0.000 claims 1
- ACHCMXBSPWFSTG-UHFFFAOYSA-N 9-cyclopentyl-2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5-ethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CCOC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(CC)C(=O)CCN2C1CCCC1 ACHCMXBSPWFSTG-UHFFFAOYSA-N 0.000 claims 1
- JPPAAAXZOZVWJV-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,8-dimethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CC(C)N2C1CCCC1 JPPAAAXZOZVWJV-UHFFFAOYSA-N 0.000 claims 1
- OJWZTBKXQCIUGC-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8-methyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CC(C)N2C1CCCC1 OJWZTBKXQCIUGC-UHFFFAOYSA-N 0.000 claims 1
- DIKJXQJRGJEYBE-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5,8-dimethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CC(C)N2C1CCCC1 DIKJXQJRGJEYBE-UHFFFAOYSA-N 0.000 claims 1
- DDNLIQKMQDMWSC-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-8-methyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1NC(=O)CC(C)N2C1CCCC1 DDNLIQKMQDMWSC-UHFFFAOYSA-N 0.000 claims 1
- FNISJKXTBDDMGF-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4-hydroxy-4-methylpiperidin-1-yl)-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(C)(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 FNISJKXTBDDMGF-UHFFFAOYSA-N 0.000 claims 1
- KBILTEUAXWLXKP-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 KBILTEUAXWLXKP-UHFFFAOYSA-N 0.000 claims 1
- LTQRUCOWRVPXHK-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CC(C)OC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 LTQRUCOWRVPXHK-UHFFFAOYSA-N 0.000 claims 1
- RSYDNACOROMVHV-UHFFFAOYSA-N 9-cyclopentyl-2-[4-[2-hydroxyethyl(methyl)amino]-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N(C)CCO)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 RSYDNACOROMVHV-UHFFFAOYSA-N 0.000 claims 1
- PPPDATIUXAGJGR-UHFFFAOYSA-N 9-cyclopentyl-2-[4-[3-hydroxypropyl(methyl)amino]-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N(C)CCCO)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 PPPDATIUXAGJGR-UHFFFAOYSA-N 0.000 claims 1
- POBSLBATAWVCHO-UHFFFAOYSA-N 9-cyclopentyl-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyanilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(N2CCN(CCO)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 POBSLBATAWVCHO-UHFFFAOYSA-N 0.000 claims 1
- OKQDXMMMFVXHAW-UHFFFAOYSA-N 9-cyclopentyl-5-ethyl-2-[4-(4-hydroxypiperidin-1-yl)-2-propan-2-yloxyanilino]-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CCC(=O)N(CC)C2=CN=C1NC(C(=C1)OC(C)C)=CC=C1N1CCC(O)CC1 OKQDXMMMFVXHAW-UHFFFAOYSA-N 0.000 claims 1
- YODJTHMUSBWPPF-UHFFFAOYSA-N 9-fluoro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-11-methyl-5h-pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC(F)=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 YODJTHMUSBWPPF-UHFFFAOYSA-N 0.000 claims 1
- VOMMOJXYDRSJDB-UHFFFAOYSA-N 9-fluoro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC(F)=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 VOMMOJXYDRSJDB-UHFFFAOYSA-N 0.000 claims 1
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims 1
- MJWFWWQYJUYLME-UHFFFAOYSA-N C12CCCC2C(=O)N(C)C2=CN=C(NCCO)N=C2N1C1CCCC1 Chemical compound C12CCCC2C(=O)N(C)C2=CN=C(NCCO)N=C2N1C1CCCC1 MJWFWWQYJUYLME-UHFFFAOYSA-N 0.000 claims 1
- WRHUGGCQUAYYDQ-UHFFFAOYSA-N C1CN(C)CCC1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 Chemical compound C1CN(C)CCC1NC1=NC=C(N(C)C(=O)C2C(CCC2)N2C3CCCC3)C2=N1 WRHUGGCQUAYYDQ-UHFFFAOYSA-N 0.000 claims 1
- OCLDKOPBXYVCHQ-UHFFFAOYSA-N C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 OCLDKOPBXYVCHQ-UHFFFAOYSA-N 0.000 claims 1
- YJOJNCMEFOKLDY-UHFFFAOYSA-N C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CN=CC=C4C(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 YJOJNCMEFOKLDY-UHFFFAOYSA-N 0.000 claims 1
- JNYFWESQXFKIGG-UHFFFAOYSA-N C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OC)=CC=1N1CCN(C)CC1 JNYFWESQXFKIGG-UHFFFAOYSA-N 0.000 claims 1
- IAMXXMOPUGAJEU-UHFFFAOYSA-N C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 Chemical compound C=1C=C(NC=2N=C3N4CCCC4CC(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 IAMXXMOPUGAJEU-UHFFFAOYSA-N 0.000 claims 1
- RJWOSNXCRBEXEQ-UHFFFAOYSA-N C=1C=C(NC=2N=C3N4CCCC4CC(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 Chemical compound C=1C=C(NC=2N=C3N4CCCC4CC(=O)NC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 RJWOSNXCRBEXEQ-UHFFFAOYSA-N 0.000 claims 1
- LFZHXUKTGCSQNI-UHFFFAOYSA-N CC(C)OC1=CC(C(=O)N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 Chemical compound CC(C)OC1=CC(C(=O)N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 LFZHXUKTGCSQNI-UHFFFAOYSA-N 0.000 claims 1
- WSGUAIUSADDSHS-UHFFFAOYSA-N COC1=CC(C(=O)N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 Chemical compound COC1=CC(C(=O)N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 WSGUAIUSADDSHS-UHFFFAOYSA-N 0.000 claims 1
- JGDSAHBYNOMOSG-UHFFFAOYSA-N COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 Chemical compound COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C1CCCC1N2C1CCCC1 JGDSAHBYNOMOSG-UHFFFAOYSA-N 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 claims 1
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims 1
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 claims 1
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 claims 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 1
- 101001051723 Homo sapiens Ribosomal protein S6 kinase alpha-6 Proteins 0.000 claims 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 claims 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 claims 1
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 claims 1
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims 1
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 claims 1
- 101000838596 Homo sapiens Serine/threonine-protein kinase TAO3 Proteins 0.000 claims 1
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 claims 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims 1
- IWMCPJZTADUIFX-UHFFFAOYSA-N LRRK2-IN-1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N(CC1)CCC1N1CCN(C)CC1 IWMCPJZTADUIFX-UHFFFAOYSA-N 0.000 claims 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims 1
- WELBJLUKWAJOQV-UHFFFAOYSA-N Mps1-IN-2 Chemical compound CCOC1=CC(N2CCC(O)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 WELBJLUKWAJOQV-UHFFFAOYSA-N 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- STZBUZVVUVRUEG-UHFFFAOYSA-N N1=C2N(C3CCCC3)C3CCCC3C(=O)N(C)C2=CN=C1NC1CCC(O)CC1 Chemical compound N1=C2N(C3CCCC3)C3CCCC3C(=O)N(C)C2=CN=C1NC1CCC(O)CC1 STZBUZVVUVRUEG-UHFFFAOYSA-N 0.000 claims 1
- LGYXPNASGGUQDS-UHFFFAOYSA-N N1=C2N3CCCC3CC(=O)N(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 Chemical compound N1=C2N3CCCC3CC(=O)N(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(O)CC1 LGYXPNASGGUQDS-UHFFFAOYSA-N 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 101150117329 NTRK3 gene Proteins 0.000 claims 1
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 claims 1
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 108030005449 Polo kinases Proteins 0.000 claims 1
- 108010003506 Protein Kinase D2 Proteins 0.000 claims 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 claims 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 1
- 101150071831 RPS6KA1 gene Proteins 0.000 claims 1
- 102100024897 Ribosomal protein S6 kinase alpha-6 Human genes 0.000 claims 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims 1
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 claims 1
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 claims 1
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 claims 1
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims 1
- 102100028948 Serine/threonine-protein kinase TAO1 Human genes 0.000 claims 1
- 101710106079 Serine/threonine-protein kinase TAO1 Proteins 0.000 claims 1
- 102100028954 Serine/threonine-protein kinase TAO3 Human genes 0.000 claims 1
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 claims 1
- 101150052413 TNK2 gene Proteins 0.000 claims 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- MCHVYRYQCRDWGJ-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-[(5,11-dimethyl-6-oxopyrimido[4,5-b][1,4]benzodiazepin-2-yl)amino]-4-methoxybenzamide Chemical compound COC1=CC=C(C(=O)NCCN(C)C)C=C1NC1=NC=C(N(C)C(=O)C=2C(=CC=CC=2)N2C)C2=N1 MCHVYRYQCRDWGJ-UHFFFAOYSA-N 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 0 C*(C)(C)CC(CC1)C(C2*)N1c(nc(NI)nc1*)c1N(C)C2=O Chemical compound C*(C)(C)CC(CC1)C(C2*)N1c(nc(NI)nc1*)c1N(C)C2=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19390109P | 2009-01-06 | 2009-01-06 | |
| US61/193,901 | 2009-01-06 | ||
| PCT/US2010/000050 WO2010080712A2 (en) | 2009-01-06 | 2010-01-06 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134522A Division JP6125571B2 (ja) | 2009-01-06 | 2015-07-03 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012514601A JP2012514601A (ja) | 2012-06-28 |
| JP2012514601A5 true JP2012514601A5 (enExample) | 2013-02-28 |
| JP5908728B2 JP5908728B2 (ja) | 2016-04-26 |
Family
ID=42317095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011544638A Active JP5908728B2 (ja) | 2009-01-06 | 2010-01-06 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
| JP2015134522A Active JP6125571B2 (ja) | 2009-01-06 | 2015-07-03 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134522A Active JP6125571B2 (ja) | 2009-01-06 | 2015-07-03 | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9266890B2 (enExample) |
| EP (3) | EP2379559B1 (enExample) |
| JP (2) | JP5908728B2 (enExample) |
| CA (1) | CA2748181C (enExample) |
| WO (1) | WO2010080712A2 (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| EP2379559B1 (en) * | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| TWI557127B (zh) | 2009-09-04 | 2016-11-11 | 百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| AU2011260323A1 (en) | 2010-06-04 | 2012-11-15 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as LRRK2 modulators |
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US9351974B2 (en) | 2011-11-10 | 2016-05-31 | OSI Pharmaceuticals, LLC | Substituted pteridinones for the treatment of cancer |
| EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| US20130259785A1 (en) * | 2012-03-30 | 2013-10-03 | Alstom Technology Ltd | Method and system for carbon dioxide removal |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| EA025186B1 (ru) | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014031872A2 (en) * | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014160430A1 (en) * | 2013-03-13 | 2014-10-02 | Georgetown University | Small molecule lrrk2 and erk5 inhibitors |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| EP2970317A4 (en) * | 2013-03-15 | 2016-11-02 | Dana Farber Cancer Inst Inc | PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| US9801880B2 (en) * | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EP3099693A4 (en) * | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| WO2015129927A1 (en) * | 2014-02-26 | 2015-09-03 | Kyorin Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| GB201411581D0 (en) * | 2014-06-30 | 2014-08-13 | Inst Europ Di Oncologia S R L | Compounds inhibiting the enzyme monopolar spindle 1 kinase, pharmaceutical compositions and uses thereof |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| EP3166637B1 (en) * | 2014-07-10 | 2020-01-29 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
| WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| RU2017104897A (ru) * | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| UA122130C2 (uk) | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
| CA2968464A1 (en) | 2014-11-25 | 2016-06-02 | Bayer Pharma Aktiengesellschaft | Substituted pyridobenzodiazepinone-derivatives and use thereof |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| WO2017069279A1 (ja) * | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| JP2019512459A (ja) * | 2016-03-04 | 2019-05-16 | アンホイ ニュー スター ファーマシューティカル デベロップメント カンパニー，リミテッド | ７員環化合物、その調製方法、その医薬組成物、およびその使用 |
| AU2017248186B2 (en) * | 2016-04-07 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| CA3031443A1 (en) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors |
| EP3490552B1 (en) * | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CN109982687A (zh) | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| CA3040173A1 (en) * | 2016-10-18 | 2018-04-26 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| SG11201908234WA (en) | 2017-02-24 | 2019-10-30 | Daegu Gyeongbuk Medical Innovation Found | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CA3087716A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| CA3087288A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN109999763A (zh) * | 2019-03-20 | 2019-07-12 | 广西民族大学 | 一种去除糖浆中钙镁离子的方法 |
| WO2020206608A1 (en) | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| ES3034869T3 (en) * | 2019-04-22 | 2025-08-25 | Univ Pittsburgh Commonwealth Sys Higher Education | Tg02 for use in treating gliomas in pediatric subjects |
| US12365696B2 (en) | 2019-05-10 | 2025-07-22 | Dana-Farber Cancer Institute, Inc. | Small-molecule focal adhesion kinase (FAK) inhibitors |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20220280530A1 (en) * | 2019-08-08 | 2022-09-08 | Anhui Newstar Pharmaceutical Development Co., Ltd. | Prevention or treatment of diseases and disorders associated with tissue damage |
| AU2020356484A1 (en) | 2019-09-27 | 2022-03-17 | Dana-Farber Cancer Institute, Inc. | ERK5 degraders as therapeutics in cancer and inflammatory diseases |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102498531B1 (ko) * | 2020-06-29 | 2023-02-13 | 한국과학기술연구원 | 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체 |
| WO2022036313A1 (en) * | 2020-08-14 | 2022-02-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Pyrimidinyl sulfonamides as inhibitors of ack1/tnk1 tyrosine kinase |
| US12630535B2 (en) | 2020-08-14 | 2026-05-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ACK1/TNK2 tyrosine kinase |
| EP4229061A4 (en) * | 2020-10-14 | 2024-09-25 | Ranok Therapeutics (Hangzhou) Co. Ltd. | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION |
| WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| CN114478539B (zh) * | 2022-02-09 | 2024-02-02 | 中国人民解放军海军军医大学 | 一种新型dclk1抑制剂及其制备方法和应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN116173040B (zh) * | 2022-08-23 | 2025-05-23 | 杭州天玑济世生物科技有限公司 | Xmd17109作为arih1激动剂的用途 |
| CN116375713B (zh) * | 2023-03-07 | 2024-11-19 | 中国人民解放军海军军医大学 | 一种dclk1蛋白降解靶向嵌合体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69939168D1 (de) * | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| DE50307267D1 (de) * | 2003-02-26 | 2007-06-21 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| DE102005061655A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Diazepinone |
| ATE479434T1 (de) | 2006-02-14 | 2010-09-15 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| CN101636399B (zh) | 2007-03-22 | 2012-04-18 | 武田药品工业株式会社 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
| WO2009067547A1 (en) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2379559B1 (en) * | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
-
2010
- 2010-01-06 EP EP10729389.6A patent/EP2379559B1/en active Active
- 2010-01-06 EP EP21152496.2A patent/EP3828185B1/en active Active
- 2010-01-06 US US13/143,505 patent/US9266890B2/en active Active
- 2010-01-06 WO PCT/US2010/000050 patent/WO2010080712A2/en not_active Ceased
- 2010-01-06 EP EP17178398.8A patent/EP3255047B1/en active Active
- 2010-01-06 JP JP2011544638A patent/JP5908728B2/ja active Active
- 2010-01-06 CA CA2748181A patent/CA2748181C/en active Active
-
2015
- 2015-07-03 JP JP2015134522A patent/JP6125571B2/ja active Active
-
2016
- 2016-01-13 US US14/994,213 patent/US9464091B2/en active Active
- 2016-08-08 US US15/231,209 patent/US9701683B2/en active Active
-
2017
- 2017-05-25 US US15/605,515 patent/US10081639B2/en active Active
-
2018
- 2018-08-22 US US16/108,725 patent/US10570154B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200624T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka | |
| JP7624985B2 (ja) | Ｐｒｍｔ５阻害剤の組合せ医薬 | |
| KR20240167633A (ko) | 종양 치료용 약학 조성물 | |
| US20200054635A1 (en) | Combination therapies with ehmt2 inhibitors | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| RU2502737C2 (ru) | Производные имидазопиридина или имидазопиримидина в качестве ингибиторов фосфодиэстеразы 10а | |
| ZA202001390B (en) | Crystalline forms | |
| CN106243088B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| TW201032806A (en) | Hsp90 inhibitor combinations | |
| RU2007137983A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| EA036446B1 (ru) | Соединения и композиции для подавления активности shp2 | |
| AU2014372166A1 (en) | Pharmaceutical combinations | |
| KR20120062839A (ko) | 단백질 키나제 억제제로서의 화합물 및 조성물 | |
| JP2013542963A5 (enExample) | ||
| NZ610018A (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| EA200901505A1 (ru) | 3,6-дизамещенные имидазо[1,2-b]пиридазины и 3,5-дизамещенные пиразоло[1,5-a]пиримидины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| TW200930374A (en) | Pyrrolo[3,2-d]pyrimidine compounds and their use as PI3 kinase and mTOR kinase inhibitors | |
| US20150164910A1 (en) | Antiviral compounds and methods of use | |
| CN109414506B (zh) | 用于治疗癌症的药物组合 | |
| CA2850707C (en) | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome | |
| US11505555B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| TW201240665A (en) | Use of active pharmaceutical compounds for the treatment of central nervous system conditions | |
| JP2007509158A5 (enExample) | ||
| AU2011323899A1 (en) | Methods of treatment and/or prevention of scleroderma, UV injury or sunburn, formation of scars or keloids by using haloaryl substituted Aminopurines |